Particle Sciences To Offer SoluBest Technology

Particle Sciences Inc. (PSI) and SoluBest have entered into a licensing and technology development agreement under which PSI will be the exclusive contract research provider in the U.S. for SoluBest’s Solumer technology. PSI will offer Solumer formulation and clinical trial supply manufacturing to pharma/biopharma companies. The Solumer approach uses GRAS polymers to create drug/polymer complexes that, according to the company, result in greatly improved drug solubility and bioavailability. Once formulations come in contact with aqueous media, they spontaneously form colloidal dispersions, resulting in increased bioavailability of the active pharmaceutical ingredient. The process is adaptable to a wide range of molecules.

Amir Zalcenstein, SoluBest’s chief executive officer, said, “We are thrilled to partner with Particle Sciences. They are at the cutting edge of drug delivery technologies and provide us with greater access to the U.S. marketplace. Additionally, by leveraging their significant GMP/GLP infrastructure, we are able to offer potential licensees a clear development path with a world-class CRO. Moreover, following our recent licensing deal with Dr. Reddy’s, we’re seeing a lot of interest in our technology, and partnering with Particle Sciences is essential in order to meet the increased demand.”

Mark Mitchnick, chief executive officer of Particle Sciences, added, “The Solumer technology fits perfectly with our growth strategy of adopting truly value added drug delivery approaches to our portfolio. This is a proven technology that is both cost effective and scalable. It will find application with both NCEs and generics. Under this agreement, Particle Sciences will use Solumer technology to develop drug products for our clients. We are very excited to be working with SoluBest and are already evaluating the technology for specific projects.”